Navigation Links
U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International

PLEASANTON, Calif., FRAMINGHAM, Mass. and SYDNEY, July 29 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, and HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), which develops and manufactures miniaturized implantable heart pumps, announced today that the United States Federal Trade Commission ("FTC") has informed them that the FTC will file a complaint in U.S. Federal District Court to challenge Thoratec's proposed acquisition of HeartWare International.

Thoratec and HeartWare International are disappointed with the FTC's decision to challenge the acquisition. The companies intend to review the FTC's decision and mutually assess the appropriate next steps and promptly communicate their intentions once a decision has been made.

About Thoratec Corporation

Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate LVAS, with more than 13,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at or

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation, and IVAD is a trademark of Thoratec Corporation.

About HeartWare International, Inc.

HeartWare International develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs) to treat patients suffering from advanced heart failure. HeartWare's HVAD(TM) pump is the only full-output pump designed to be implanted in the chest. HeartWare has completed an international clinical trial for the device involving five investigational centers in Europe and Australia. The device is currently the subject of a 150-patient clinical trial in the United States for a bridge-to-transplantation indication.

Additional Information and Where You Can Find It

Thoratec has filed a Registration Statement on Form S-4 containing a proxy statement/prospectus and other documents concerning the proposed acquisition with the Securities and Exchange Commission (the "SEC"). The proxy statement, once finalized, will be filed by HeartWare with the SEC and mailed by HeartWare to its stockholders. Investors are urged to read the proxy statement/prospectus and other relevant documents filed with the SEC because they contain important information. Security holders may obtain a free copy of the proxy statement/prospectus (when it is available) and other documents filed by Thoratec and HeartWare with the SEC at the SEC's web site at The proxy statement/prospectus and other documents may also be obtained for free by contacting Thoratec Investor Relations by e-mail at or by telephone at 925-847-8600 or by contacting HeartWare Investor Relations by e-mail at or by telephone at 61 2 9238 2064.

Thoratec, HeartWare and their respective directors, executive officers, certain members of management and certain employees may be deemed to be participants in the solicitation of proxies in connection with the proposed merger. A description of the interests in HeartWare of its directors and executive officers is set forth in HeartWare's proxy statement for its 2009 Annual Meeting of Stockholders, which was filed with the SEC on June 11, 2009, and the Annual Report on Form 10-K for the fiscal year ended December 31, 2008, which was filed with the SEC on February 26, 2009 and amended on April 29, 2009. These documents are available free of charge at the SEC's web site at or by contacting HeartWare Investor Relations by e-mail at or by telephone at 61 2 9238 2064. Information concerning Thoratec's directors and executive officers is set forth in Thoratec's proxy statement for its 2009 Annual Meeting of Shareholders, which was filed with the SEC on April 15, 2009. This document is available free of charge at the SEC's web site at or by going to Thoratec's Investors page on its corporate web site at Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed merger, and a description of their direct and indirect interests in the proposed merger, which may differ from the interests of HeartWare stockholders or Thoratec shareholders, generally will be set forth in the proxy statement/prospectus when it is filed with the SEC.

Use of Forward-Looking Statements

This document includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "projects," "hopes," "could," "will," "intends," "should," "estimate," "would," "may," "anticipates," "plans" and other similar words. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking information, and are based on Thoratec's current expectations, estimates, forecasts and projections. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: failure of HeartWare's stockholders to approve the proposed transaction; and other economic, business, competitive, and/or regulatory factors affecting the businesses of Thoratec and HeartWare generally, including those set forth in the filings of Thoratec and HeartWare with the Securities and Exchange Commission, especially in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of their respective annual reports on Form 10-K and quarterly reports on Form 10-Q, their current reports on Form 8-K and other SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions or updates to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Ricky Takai, Expert in Designing and Managing Federal Evaluation Studies in Education, Joins Abt Associates
2. Maureen Mo Zilly Joins the Varian Medical Systems Government Affairs Team as Director, Federal Affairs
3. Panel blasts federal nanotech risk research strategy
4. Lilly to Take Charge to Earnings Related to Pending Federal and State Investigations of Past Practices
5. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
6. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
7. Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases
8. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
9. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
10. Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians
11. Federal government taps NC State experts to explain nanotech risks
Post Your Comments:
(Date:10/8/2015)... Fla. , Oct. 8, 2015   Intrexon ... synthetic biology, today announced the appointment of Joseph ... Environment Sector, succeeding Nir Nimrodi who continues ... Vaillancourt will direct Intrexon,s endeavors to generate sustainable, biologically ... America , where he held a variety of ...
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... ... 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), announced ... commercialize intellectual property rights belonging to The University of British Columbia (UBC). This ... worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications ...
Breaking Biology Technology:
... ... product immediately, NATICK, Mass., April 14 Boston Scientific,Corporation ... Labor,and Welfare (MHLW) approval of its ACUITY(R) Steerable left ventricular,lead ... failure. The Company also received reimbursement approval for,the lead from ...
... SGP ) is scheduled to announce its sales and ... 23, 2008., At 8 a.m. (EDT) on that ... for the 2008 first quarter and provide an update ... Fred Hassan,Schering-Plough,s chairman and CEO, and other members of ...
... For 88 percent of,companies, front-line and mid-level leaders ... variety of development skills but focus,strongly on techniques ... only half of executive-level sales leaders attend the ... and,training, according to a member-driven research study conducted ...
Cached Biology Technology:
(Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
(Date:9/10/2015)... Sept. 10, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... site, Touch of Modern, will feature the Wocket® smart ... th . Touch Of Modern ... designer lifestyle products to its 7.2 million members. Customers ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... -- A team of scientists led by Washington University in ... corn, a crop vital to U.S. agriculture. The researchers have ... that should accelerate efforts to develop better crop varieties to ... , Corn, also known as maize, underlies myriads of ...
... past year, various reports from the United Nations Intergovernmental Panel ... uncertain terms that in order to achieve a stable climate ... increase in CO2 emissions in the coming decades must be ... the IPCC, the maxi-mum amount of CO2 emissions that can ...
... do nearly 1 million people taking cholesterol-lowering statins often ... rare case when a diabetic takes medication for intestinal ... basis for the purported health effects of green tea? ... clinical explanation for these and other physiological mysteries. The ...
Cached Biology News:
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Synaptotagmin, phosphoSer309...
... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Biology Products: